YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
98 hedge funds and large institutions have $107M invested in Y-mAbs Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
19% less capital invested
Capital invested by funds: $132M → $107M (-$25.2M)
Holders
98
Holding in Top 10
1
Calls
$16K
Puts
–
Top Buyers
| 1 | +$2.09M | |
| 2 | +$856K | |
| 3 | +$611K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$505K |
| 5 |
D.E. Shaw & Co
New York
|
+$402K |
Top Sellers
| 1 | -$1.66M | |
| 2 | -$556K | |
| 3 | -$500K | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$489K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$362K |